Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Long-Term Deferred Tax (2022 - 2025)

Harmony Biosciences Holdings' Long-Term Deferred Tax history spans 4 years, with the latest figure at $157.1 million for Q3 2025.

  • For Q3 2025, Long-Term Deferred Tax changed N/A year-over-year to $157.1 million; the TTM value through Sep 2025 reached $157.1 million, changed N/A, while the annual FY2024 figure was $190.4 million, 32.07% up from the prior year.
  • Long-Term Deferred Tax for Q3 2025 was $157.1 million at Harmony Biosciences Holdings, down from $201.2 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $201.2 million in Q2 2025 and bottomed at $81.7 million in Q3 2022.
  • The 4-year median for Long-Term Deferred Tax is $144.2 million (2023), against an average of $135.1 million.
  • The largest YoY upside for Long-Term Deferred Tax was 67.74% in 2023 against a maximum downside of 23.02% in 2023.
  • A 4-year view of Long-Term Deferred Tax shows it stood at $85.9 million in 2022, then soared by 67.74% to $144.2 million in 2023, then soared by 32.07% to $190.4 million in 2024, then fell by 17.5% to $157.1 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Long-Term Deferred Tax are $157.1 million (Q3 2025), $201.2 million (Q2 2025), and $194.7 million (Q1 2025).